secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0000950170-22-018857
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus appoints Anne Altmeyer, Ph.D. to Board of Directors
----------------------------------------------------------

- Dr. Altmeyer appointed to the Board effective September 20, 2022, until next annual meeting.
- She receives initial option to purchase 159,200 shares of common stock and $40,000 annual cash retainer.
- Altmeyer is President & CEO of TigaTx, former CBO at Sigilon Therapeutics and Adicet Bio, and held roles at Novartis and Baxalta.
- Appointment brings oncology R&D and corporate development expertise to Corbus pipeline expansion.
- Standard indemnification agreement executed; no reportable transactions under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017022018857/0000950170-22-018857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017022018857/crbp-20220920.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer